Edward V. Hannigan - Concepedia

Author

Edward V. Hannigan

The University of Texas Medical Branch at Galveston

Also Known As

E Hannigan, E V Hannigan, E. Hannigan, E. V. Hannigan, E.V. HANNIGAN, E.V. Hannigan, EDWARD V. HANNIGAN, Edward Hannigan, Edward V Hannigan, Edward V. Hannigan

103

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Medical Branch at Galveston SWOG Cancer Research Network Cancer Research And Biostatistics University of Arizona University of Arizona Cancer Center

About

Edward V. Hannigan is an author at The University of Texas Medical Branch at Galveston specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	32	1.5K
2	Public Health	5	5	352
3	Health Sciences	3	3	110
4	Cell Biology	1	1	51
5	Endocrinology	1	1	10

Edward V. Hannigan

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study Charles W. Whitney, William T. Sause, Brian N. Bundy, Journal of Clinical Oncology	1999	1.5K
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer David S. Alberts, P. Y. Liu, Edward V. Hannigan, New England Journal of Medicine	1996	1.2K
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. David S. Alberts, S Green, Edward V. Hannigan, Journal of Clinical Oncology	1992	299
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial Joseph T. Santoso, Joseph A. Lucci, Robert L. Coleman, Cancer Chemotherapy and Pharmacology Renal FunctionFurosemide HydrationAcute Cisplatin NephrotoxicityMedicineRandomized Trial	2003	224
4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Joachim G. Liehr, Mary Jo Ricci, C R Jefcoate, Proceedings of the National Academy of Sciences	1995	208
Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group Gary L. Eddy, Brian N. Bundy, William T. Creasman, Gynecologic Oncology Cervical Cancer ManagementSurgical OncologyCervical CancerGynecological SurgeryMedicine	2007	160
Circulating Serum Levels of Cytokines and Angiogenic Factors in Patients with Cervical Cancer Vimlarani Chopra, Tung Van Dinh, Edward V. Hannigan Cancer Investigation	1998	141
Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer Maurie Markman, Massimo Federico, Pengfei Liu, Gynecologic Oncology Early ChangesAdvanced Ovarian CancerMedicinePathologyGynecology	2006	82
Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Concepcion Diaz‐Arrastia, Istvan Arany, Sonia C. Robazetti, PubMed	2001	82
Hyperinsulinemia and Stromal Luteinization of the Ovaries in Postmenopausal Women With Endometrial Cancer* Manubai Nagamani, Edward V. Hannigan, Tung Van Dinh, The Journal of Clinical Endocrinology & Metabolism	1988	81

Page 1